TESLA
TESLA
Trial TESLA-Pilot (Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities) Aim To evaluate the efficacy and safety of evolocumab in patients with homozygous familial hypercholesterolaemia Study design Open-label, single-arm, multicentre, dose scheduling pilot studySubcutaneous evolocumab, 420 mg every 4 weeks for ≥12 weeks,…
read more »
Rationale for TESLA and results
Low density lipoprotein cholesterol (LDL-C) can be significantly reduced in patients with a serious genetic disorder – homozygous familial hypercholesterolaemia (FH) – when a PCSK9 inhibitor evolocumab is added to statins and other lipid-lowering medications. Professor Frederick Raal explains the results of the TESLA study.
read more »
Implications from TESLA for FH management
The investigational PCSK9 inhibitor evolocumab, promises to be an important new treatment for a rare but serious genetic disorder, homozygous familial hypercholesterolaemia, according to one of the investigators in the TESLA study, Professor Frederick Raal.
read more »
TESLA in brief
TESLA was a randomised, double-blind, placebo-controlled trial of the PCSK9 inhibitor, evolocumab, in 50 patients (49 received treatment) with homozygous FH (mean LDL-C at baseline 9.0 mmol/L). All were on statins and 91% also received ezetimibe. LDL receptor mutations were identified in 45 (92%) patients;…
read more »
Implications from TESLA and early TAUSSIG studies with evolocumab
Results of clinical trials of the investigational therapy – evolocumab, a PCSK9 inhibitor will potentially change care of patients at a high risk of cardiovascular disease (heart attacks), by reducing their very high low density lipoprotein cholesterol (LDL-C) levels. The Forum talks to Professor Gerald…
read more »
Rationale for TESLA and results
Low density lipoprotein cholesterol (LDL-C) can be significantly reduced in patients with a serious genetic disorder – homozygous familial hypercholesterolaemia (FH) – when a PCSK9 inhibitor evolocumab is added to statins and other lipid-lowering medications. Professor Frederick Raal explains the results of the TESLA study.
read more »
EAS Madrid: What made the clinical news about PCSK9?
TESLA: PCSK9 inhibition effective in homozygous FH Phase III TESLA study shows that treatment with the PCSK9 monoclonal antibody inhibitor evolocumab significantly lowered LDL-C by 31% at week 12 in patients with homozygous FH (HoFH) receiving intensive statin treatment and other lipid-modifying therapy. For the…
read more »
